Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dendreon Corp.
Data: Modulation of Trp-p8 significantly inhibits tumor growth in vivo
October 26th, 2005
Dendreon Corp. (DNDN) announced that new data were presented showing that modulation of the Trp-p8 tumor target with small molecules may represent a new approach to cancer therapy. In addition, the company has identified several lead candidates for future clinical study that are orally bioavailable and potent agonists of Trp-p8. The data were presented at the Ion Channel Targets Conference. Dr. Sateesh Natarajan, senior scientist at Dendreon, presented an abstract entitled, "Agonism of the Trp-p8 Ion Channel for the Treatment of Cancer," which focused on the discovery of potent and selective Trp-p8 small-molecule agonists that...
Source: Elder Law Weekly (2005-10-26)
|
